Results 11 to 20 of about 494,085 (317)

Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.

New England Journal of Medicine, 2021
BACKGROUND The Janus kinase inhibitor upadacitinib is a potential treatment for psoriatic arthritis. The efficacy and safety of upadacitinib as compared with adalimumab, a tumor necrosis factor α inhibitor, in patients who have an inadequate response to ...
I. McInnes, Jaclyn K Anderson, M. Magrey, J. Merola, Yi Liu, M. Kishimoto, S. Jeka, C. Pacheco-Tena, Xin Wang, Liang Chen, P. Zueger, John Liu, A. Pangan, F. Behrens   +13 more
semanticscholar   +1 more source

Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension Study

Arthritis & Rheumatology, 2022
To assess the long‐term safety, tolerability, and efficacy of bimekizumab in active psoriatic arthritis (PsA).
L. Coates, I. McInnes, J. Merola, R. Warren, A. Kavanaugh, A. Gottlieb, L. Gossec, D. Assudani, R. Bajracharya, J. Coarse, B. Ink, C. Ritchlin   +11 more
semanticscholar   +1 more source

Comorbidities in psoriatic arthritis: a systematic review and meta-analysis

Rheumatology International, 2021
The aims of this systematic review and meta-analysis were to: (1) describe the prevalence of commonly reported comorbidities in psoriatic arthritis (PsA), (2) compare the incidence and/or prevalence of comorbidities between PsA and control populations ...
Sonal Gupta, Zoe J Syrimi, D. Hughes, S. Zhao   +3 more
semanticscholar   +1 more source

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update

Annals of the Rheumatic Diseases, 2020
Objective To update the European League Against Rheumatism (EULAR) recommendations for the pharmacological treatment of psoriatic arthritis (PsA). Methods According to the EULAR standardised operating procedures, a systematic literature review was ...
L. Gossec, X. Baraliakos, A. Kerschbaumer, M. D. de Wit, I. McInnes, M. Dougados, J. Primdahl, D. McGonagle, D. Aletaha, A. Balanescu, P. Bálint, H. Bertheussen, W. Boehncke, G. Burmester, J. Cañete, N. Damjanov, T. Kragstrup, T. Kvien, R. Landewé, R. Lories, H. Marzo-Ortega, D. Poddubnyy, Santiago Rodrigues Manica, G. Schett, D. Veale, F. E. Van den Bosch, D. M. van der Heijde, J. Smolen   +27 more
semanticscholar   +1 more source

Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis

Arthritis & Rheumatology, 2021
To assess long‐term efficacy and safety of guselkumab, an interleukin‐23 p19 subunit (IL‐23p19) inhibitor, in patients with active psoriatic arthritis (PsA) from the phase III DISCOVER‐2 trial.
I. McInnes, P. Rahman, A. Gottlieb, E. Hsia, A. Kollmeier, Xie L. Xu, Yusang Jiang, S. Sheng, M. Shawi, S. Chakravarty, D. van der Heijde, P. Mease   +11 more
semanticscholar   +1 more source

Tissue‐Resident Memory CD8+ T Cells From Skin Differentiate Psoriatic Arthritis From Psoriasis

Arthritis & Rheumatology, 2021
To compare immune cell phenotype and function in psoriatic arthritis (PsA) versus psoriasis in order to better understand the pathogenesis of PsA.
E. Leijten, T. V. van Kempen, M. O. Olde Nordkamp, J. Pouw, N. J. Kleinrensink, N. Vincken, J. Mertens, D. Balak, F. Verhagen, S. Hartgring, E. Lubberts, J. Tekstra, A. Pandit, T. Radstake, M. Boes   +14 more
semanticscholar   +1 more source

Ustekinumab for the treatment of psoriatic arthritis: an update. [PDF]

, 2014
Psoriatic arthritis occurs in 30% of psoriasis patients, and the treatment can be challenging in some patients. Recently, the US Food and Drug Administration approved ustekinumab, a fully human monoclonal antibody, for the management of psoriatic ...
Davari, Parastoo, Fazel, Nasim, Kamangar, Faranak, Leo, Michael S   +3 more
core   +1 more source

Metabolomics in psoriatic disease: pilot study reveals metabolite differences in psoriasis and psoriatic arthritis. [PDF]

, 2014
ImportanceWhile "omics" studies have advanced our understanding of inflammatory skin diseases, metabolomics is mostly an unexplored field in dermatology.ObjectiveWe sought to elucidate the pathogenesis of psoriatic diseases by determining the differences
Armstrong, April W, Azizi, Baktazh, Dhillon, Jaskaran, Fiehn, Oliver, Grapov, Dmitry, Johnson, Mary Ann, Wu, Julie   +6 more
core   +2 more sources

Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-analysis.

JAMA dermatology, 2020
Importance The association between psoriasis and risk of cancer remains debatable. Objective To evaluate the association and risk of cancer in patients with psoriasis or psoriatic arthritis, including risk of specific cancer subtypes.
Sofie Vaengebjerg, L. Skov, A. Egeberg, N. Loft   +3 more
semanticscholar   +1 more source

Persistencia de medicamentos biológicos durante ocho años en pacientes con artritis reumatoide y espondiloartritis [PDF]

, 2019
Objective: To calculate the persistence, over a period of eight years, the retention rate of first and second-line of treatment with biological agents in patients with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis and to compare ...
Balsa, Alejandro, González-Fernández, María, Herrero, Alicia, Jiménez-Nácher, Inmaculada, Moreno, Francisco, Villamañán, Elena   +5 more
core   +3 more sources